Id |
Subject |
Object |
Predicate |
Lexical cue |
T1 |
0-174 |
Sentence |
denotes |
Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs. |
T2 |
175-186 |
Sentence |
denotes |
BACKGROUND: |
T3 |
187-299 |
Sentence |
denotes |
Acetaminophen (paracetamol--P) and Nimesulide (N) are widely used analgesic-antipyretic/anti-inflammatory drugs. |
T4 |
300-380 |
Sentence |
denotes |
The rate of adverse hypersensitivity reactions to these agents is generally low. |
T5 |
381-484 |
Sentence |
denotes |
On the contrary non-steroidal anti-inflammatory drugs (NSAIDs) are commonly involved in such reactions. |
T6 |
485-569 |
Sentence |
denotes |
Celecoxib (CE) is a novel drug, with high selectivity and affinity for COX-2 enzyme. |
T7 |
570-580 |
Sentence |
denotes |
OBJECTIVE: |
T8 |
581-742 |
Sentence |
denotes |
We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs. |
T9 |
743-751 |
Sentence |
denotes |
METHODS: |
T10 |
752-862 |
Sentence |
denotes |
We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs. |
T11 |
863-939 |
Sentence |
denotes |
The diagnosis of P and N-induced skin reactions was based in vivo challenge. |
T12 |
940-1012 |
Sentence |
denotes |
The placebo was blindly administered at the beginning of each challenge. |
T13 |
1013-1097 |
Sentence |
denotes |
After three days, a cumulative dosage of 200 mg of CE in refracted doses were given. |
T14 |
1098-1155 |
Sentence |
denotes |
After 2-3 days, a single dose of 200 mg was administered. |
T15 |
1156-1282 |
Sentence |
denotes |
All patients were observed for 6 hours after each challenge, and controlled again after 24 hours to exclude delayed reactions. |
T16 |
1283-1402 |
Sentence |
denotes |
The challenge was considered positive if one or more of the following appeared: erythema, rush or urticaria-angioedema. |
T17 |
1403-1411 |
Sentence |
denotes |
RESULTS: |
T18 |
1412-1490 |
Sentence |
denotes |
No reaction was observed with placebo and eight patients (88.8%) tolerated CE. |
T19 |
1491-1552 |
Sentence |
denotes |
Only one patient developed a moderate angioedema of the lips. |
T20 |
1553-1564 |
Sentence |
denotes |
CONCLUSION: |
T21 |
1565-1671 |
Sentence |
denotes |
Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients. |
T22 |
1672-1782 |
Sentence |
denotes |
Thus, we conclude that CE is a reasonably safe alternative to be used in subjects who do not tolerate P and N. |